Assets

Type	Time	Amount	Unit
ifrs-full:Assets	2025-12-31	93182000	vDKK
ifrs-full:Assets	2024-12-31	95984000	vDKK

Revenue

Type	Start date	End date	Amount	Unit
ifrs-full:Revenue	2025-01-01	2025-12-31	40287000	vDKK
ifrs-full:Revenue	2024-01-01	2024-12-31	36243000	vDKK

XML

See the xml submitted here:

XML: http://regnskaber.virk.dk/71300571/amNsb3VkczovLzAzLzA3LzZiL2IxLzYyL2FhODYtNGRmMi1iMGU3LTk5NzQzYmVkOTg5MQ.xml

Separator

The full data:

<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance"
            xmlns="http://www.w3.org/1999/xhtml"
            xmlns:arr="http://xbrl.dcca.dk/arr"
            xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16"
            xmlns:cmn="http://xbrl.dcca.dk/cmn"
            xmlns:sob="http://xbrl.dcca.dk/sob"
            xmlns:link="http://www.xbrl.org/2003/linkbase"
            xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full"
            xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
            xmlns:bioporto="https://bioporto.com"
            xmlns:ix="http://www.xbrl.org/2013/inlineXBRL"
            xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
            xmlns:mrv="http://xbrl.dcca.dk/mrv"
            xmlns:fsa="http://xbrl.dcca.dk/fsa"
            xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
            xmlns:gsd="http://xbrl.dcca.dk/gsd"
            xmlns:xlink="http://www.w3.org/1999/xlink"
            id="DKGAAP">
   <link:schemaRef xlink:href="http://archprod.service.eogs.dk/taxonomy/20241001/entryDanishGAAPExcludingBalanceSheetIncomeStatementIncludingManagementsReview20241001.xsd"
                   xlink:type="simple"/>
   <xbrli:context id="ctx1">
      <xbrli:entity>
         <xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2025-01-01</xbrli:startDate>
         <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx36">
      <xbrli:entity>
         <xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2024-01-01</xbrli:startDate>
         <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx29">
      <xbrli:entity>
         <xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2025-01-01</xbrli:startDate>
         <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
         <xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfExecutiveBoardDimension">
            <cmn:memberOfBoardIdentifier>0</cmn:memberOfBoardIdentifier>
         </xbrldi:typedMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx30">
      <xbrli:entity>
         <xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2025-01-01</xbrli:startDate>
         <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
         <xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfExecutiveBoardDimension">
            <cmn:memberOfBoardIdentifier>1</cmn:memberOfBoardIdentifier>
         </xbrldi:typedMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx31">
      <xbrli:entity>
         <xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2025-01-01</xbrli:startDate>
         <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
         <xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfExecutiveBoardDimension">
            <cmn:memberOfBoardIdentifier>2</cmn:memberOfBoardIdentifier>
         </xbrldi:typedMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx32">
      <xbrli:entity>
         <xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2025-01-01</xbrli:startDate>
         <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
         <xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
            <cmn:memberOfBoardIdentifier>0</cmn:memberOfBoardIdentifier>
         </xbrldi:typedMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx33">
      <xbrli:entity>
         <xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2025-01-01</xbrli:startDate>
         <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
         <xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
            <cmn:memberOfBoardIdentifier>1</cmn:memberOfBoardIdentifier>
         </xbrldi:typedMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx34">
      <xbrli:entity>
         <xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2025-01-01</xbrli:startDate>
         <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
         <xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
            <cmn:memberOfBoardIdentifier>2</cmn:memberOfBoardIdentifier>
         </xbrldi:typedMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx35">
      <xbrli:entity>
         <xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2025-01-01</xbrli:startDate>
         <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
         <xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
            <cmn:memberOfBoardIdentifier>3</cmn:memberOfBoardIdentifier>
         </xbrldi:typedMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx38">
      <xbrli:entity>
         <xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2025-01-01</xbrli:startDate>
         <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
         <xbrldi:typedMember dimension="cmn:IdentificationOfAuditorDimension">
            <cmn:auditorIdentifier>1</cmn:auditorIdentifier>
         </xbrldi:typedMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx37">
      <xbrli:entity>
         <xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2025-01-01</xbrli:startDate>
         <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
         <xbrldi:typedMember dimension="cmn:IdentificationOfAuditorDimension">
            <cmn:auditorIdentifier>0</cmn:auditorIdentifier>
         </xbrldi:typedMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:unit id="pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
   </xbrli:unit>
   <gsd:IdentificationNumberCvrOfReportingEntity contextRef="ctx1" id="fact2361" xml:lang="en">17500317</gsd:IdentificationNumberCvrOfReportingEntity>
   <gsd:LegalEntityIdentifierOfReportingEntity contextRef="ctx1" id="fact2362" xml:lang="en">5299004SWFL5JAN4W830</gsd:LegalEntityIdentifierOfReportingEntity>
   <gsd:ReportingPeriodStartDate contextRef="ctx1" id="fact2363" xml:lang="en">2025-01-01</gsd:ReportingPeriodStartDate>
   <gsd:ReportingPeriodEndDate contextRef="ctx1" id="fact2364" xml:lang="en">2025-12-31</gsd:ReportingPeriodEndDate>
   <gsd:PrecedingReportingPeriodStartDate contextRef="ctx1" id="fact2365" xml:lang="en">2024-01-01</gsd:PrecedingReportingPeriodStartDate>
   <gsd:PredingReportingPeriodEndDate contextRef="ctx1" id="fact2366" xml:lang="en">2024-12-31</gsd:PredingReportingPeriodEndDate>
   <fsa:ClassOfReportingEntity contextRef="ctx1" id="fact2367" xml:lang="en">Regnskabsklasse D</fsa:ClassOfReportingEntity>
   <gsd:InformationOnTypeOfSubmittedReport contextRef="ctx1" id="fact2368" xml:lang="en">Annual report</gsd:InformationOnTypeOfSubmittedReport>
   <gsd:IdentificationNumberCvrOfSubmittingEnterprise contextRef="ctx1" id="fact2369" xml:lang="en">17500317</gsd:IdentificationNumberCvrOfSubmittingEnterprise>
   <gsd:NameOfSubmittingEnterprise contextRef="ctx1" id="fact2370" xml:lang="en">Bioporto A/S</gsd:NameOfSubmittingEnterprise>
   <gsd:AddressOfSubmittingEnterpriseStreetAndNumber contextRef="ctx1" id="fact2371" xml:lang="en">Tuborg Havnevej  15, st.</gsd:AddressOfSubmittingEnterpriseStreetAndNumber>
   <gsd:AddressOfSubmittingEnterprisePostcodeAndTown contextRef="ctx1" id="fact2372" xml:lang="en">2900 Hellerup</gsd:AddressOfSubmittingEnterprisePostcodeAndTown>
   <gsd:ToolForPreparingTheXBRLInstanceDocument contextRef="ctx1" id="fact2373" xml:lang="en">xWizard version 1.1.1513.0, by EasyX Aps. www.easyx.eu</gsd:ToolForPreparingTheXBRLInstanceDocument>
   <cmn:TypeOfAuditorAssistance contextRef="ctx1" id="fact2374" xml:lang="en">Auditor's report on audited financial statements</cmn:TypeOfAuditorAssistance>
   <arr:TypeOfBasisForModifiedOpinionOnAuditedFinancialStatements contextRef="ctx1" id="fact2375" xml:lang="en">Basis for Opinion</arr:TypeOfBasisForModifiedOpinionOnAuditedFinancialStatements>
   <arr:TypeOfModifiedOpinionOnAuditedFinancialStatements contextRef="ctx1" id="fact2376" xml:lang="en">Opinion</arr:TypeOfModifiedOpinionOnAuditedFinancialStatements>
   <fsa:AverageNumberOfEmployees contextRef="ctx1" decimals="0" id="fact2403" unitRef="pure">46</fsa:AverageNumberOfEmployees>
   <fsa:AverageNumberOfEmployees contextRef="ctx36" decimals="0" id="fact2628" unitRef="pure">38</fsa:AverageNumberOfEmployees>
   <gsd:NameOfReportingEntity contextRef="ctx1" id="fact1915" xml:lang="en">BioPorto A/S</gsd:NameOfReportingEntity>
   <mrv:CorporateGovernanceReport contextRef="ctx1" id="fact1002" xml:lang="en">Corporate   Governance   BioPorto remains focused on good corporate governance, having imple-   mented all, except for three recommendations from the Committee of   Corporate Governance (Komitéen for god selskabsledelse) for companies   listed on the Nasdaq Copenhagen Stock Exchange. Details can be found   in the Corporate Governance report.   The Board of Directors believes that the Company operates in compliance   with guidelines and recommendations that support the Company’s business   model and can create value for BioPorto’s stakeholders.   Regularly and at least once a year, the Board of Directors monitors adherence   to the recommendations on corporate governance to ensure appropriate   utilization of and compliance with the recommendations and legislation.   In accordance with Section 107b of the Danish Financial Statements Act,   BioPorto has published a statutory report on Corporate Governance for   the financial year 2025 on the Company’s website.   Find out more about BioPorto at   bioporto.com/corporate-governance   Board of Directors &amp; Executive   Management   BioPorto is managed in a two-tier structure composed of the Board   of Directors and the Executive Management   Board of Directors   The General Meeting elects between three and seven   members to the Board of Directors, which currently consists   of four members. The Board of Directors elects a chairperson   and a vice chairperson. Members hold office for terms of one   year at a time and may be re-elected. Members of the Board   are nominated and stand for election based on their specific   qualifications and of relevance to BioPorto. The Board of   Directors is composed of providing a combination of relevant   industry experience and functional experience. All current   Board members, except for Donna Haire, are considered   independent persons and can thus act independently. Each   Board member’s qualifications are listed on the Company’s   website.   The Board is responsible for the overall strategic management   and the financial and managerial supervision of BioPorto, and   regular evaluation of Executive Management. The Board of   Directors also ensures that the Company is properly managed   as required by the Articles of Association, other guidelines,   policies and applicable rules and regulations. Furthermore, the   Board of Directors makes decisions on all unusual matters or   matters with far-reaching implications. The Board of Directors   defines guidelines for the distribution of responsibilities   between the Board of Directors and Executive Management   but does not participate in the day-to-day management of the   Company. The duties of the Board of Directors are described   in the Rules of Procedure.   Executive Management   The Executive Management is appointed by the Board of   Directors, which lays down the Executive Managements terms   and conditions of employment and the framework for their   duties. The Executive Management is responsible for the day-   to-day management of the Company in compliance with the   guidelines and directions issued by the Board. The day-to-day   operations do not include transactions of an unusual nature   or of material importance to the affairs of the Company.   The Board is responsible for the overall   strategic management and the financial   and managerial supervision of BioPorto, and   regular evaluation of Executive Management.   Evaluation of the Performance   of the Board of Directors and the   Executive Management   Annually, the Board of Directors conducts a self-evaluation of   the Board's performance and composition. The Chair heads the   annual evaluation, which at least every third year is conducted   by an external consultant. The process, whether it is facilitated   internally or by external consultants, evaluates topics such as   board dynamics, board agenda, quality of the material that is   submitted to the Board, discussions at the Board meetings, the   Chair’s leadership of the Board, strategy, Board composition   and Board competencies. Typically, the process is further   facilitated by each Board member completing a detailed   questionnaire, and the Board members are asked to score to   which extent they agree to the individual questions.   The results of the questionnaire are then discussed at a   subsequent Board meeting, and the individual comments   submitted are used in the planning and handling of future   Board meetings. The 2025 self-evaluation was conducted   internally, and the key conclusions were positive with   continued satisfaction with the Board’s work as well as the   work on the committees. Long term planning to secure future   board competencies that align with the Companys future   strategic direction and developement will be focus area in   2026.   Remuneration Policy   and Report   The remuneration of the Board and the Executive Mana-   gement is governed by the Company’s Remuneration Policy,   which was updated in 2023, and subsequently approved by   the shareholders at the Annual General Meeting in 2023.   In accordance with section 139b in the Danish Companies   Act, BioPorto has prepared a Remuneration Report on the   remuneration of the individual members of the Board and   the Executive Management in 2025.   Business Ethics   The Company has established a Code of Conduct that is   made available to external stakeholders via the Company’s   website. Likewise, the Company has established   a Whistleblower Scheme that is available to all employees in   the BioPorto Group, both were reviewed and approved by   the Board of Directors in 2025.  </mrv:CorporateGovernanceReport>
   <mrv:StatementOfPolicyForDataEthics contextRef="ctx1" id="fact1107" xml:lang="en">Privacy, GDPR and Data Ethics   BioPorto focuses on privacy and protection of personal data   throughout the Company, covering the data of employees,   partners, and other stakeholders. BioPorto has implemented   strong measures to protect personal data and comply with the   EU General Data Protection Regulation (GDPR) and national   personal data protection legislation.   BioPorto has adopted a Data Ethics Policy cf. section 99 d of   the Danish Financial Statements Act which set out BioPorto’s   approach to data ethics and describe the ethical principles that   BioPorto and its group companies must adhere to when using   data and applying new technologies. BioPorto is dedicated to   ensuring strong data ethics based on the following principles:   1. Responsible and accountable data processing   2. Transparency   3. Data quality awareness and integrity   4. Security   5. Ethical data processing carried out by third parties   Our Data Ethics Policy is available on BioPorto’s website.   In 2025, we carried out initiatives to support our focus on   protection of personal data and data ethics principles. All new   and current employees received GDPR and data training as   part of their introductory program in 2025 and continuous   e-learning within the Company to maintain continuous   attention to data protection and data ethics principles.   We continued to implement enhancements to our policies   and procedures to support the handling and processing of   personal data.   The Board of Directors has adopted a policy on data   ethics that is available on the Company’s website.  </mrv:StatementOfPolicyForDataEthics>
   <mrv:DescriptionOfPoliciesOnSocialResponsibility contextRef="ctx1" id="fact1137" xml:lang="en">UN Global Compact   BioPorto is committed to our social responsibility and strives to   improve social and environmental conditions   UN Global Compact   BioPorto is committed to our social responsibility and strives   to improve social and environmental conditions.   BioPorto adheres to the 10 principles provided by the UN   Global Compact, with the latest Communication on Progress   available at United Nations Global compact.   BioPorto complies with the Section 99a of the Danish Financial   Statements Act of 2018.   In some areas, BioPorto fulfills its responsibility solely by   complying with current law. In other areas, the Company’s   responsibility has been expanded to include preventive   activities. It is important to BioPorto to share these efforts   to ensure that the outside world can have confidence in the   Company and that we live up to our social responsibility.   BioPorto's ongoing participation in the UN Global Compact   reinforces these principles as a global standard for social   engagement.   Human Rights   1. Businesses should support and respect the protection  of internationally proclaimed human rights; and   2. make sure that they are not complicit in human rights  abuses.   BioPorto actively supports and respects internationally   recognized human rights and labor standards. The Company   oppose all forms of discrimination and ensure equal treatment   regardless of gender, age, ethnicity, disability, religion, or   personal beliefs.   Key 2025 Highlights:   • Zero human rights violations recorded.   • Annual review and Board approval of our Code of   Conduct.   • Continued operation of the Whistleblower Scheme,   ensuring confidential reporting of concerns.   Looking ahead to 2026, BioPorto will continue to strengthen   internal controls, enhance governance processes, and   promote a safe, inclusive workplace through collaboration   with the statutory Work Environment Group.   Code of Conduct &amp;   Whistleblower Scheme   Our compliance framework is anchored in the Code of   Conduct, binding for all employees and integrated into   supplier contracts. Training on human rights and compliance   is part of onboarding and reinforced through The Company   QMS.   The Whistleblower Scheme, implemented in 2023, provides   a secure channel for reporting unethical behavior, including   harassment, discrimination, and violence of Code of Conduct.   No incidents were reported in 2025, underscoring our   commitment to transparency and accountability.   Clinical Trials   BioPorto conducts clinical trials with the highest ethical and   scientific standards. Following the first patient enrollment   in our Adult Clinical Study in 2024, trials continued in 2025   with zero reported violations. Participant safety remains our   top priority.   Human Rights Initiatives   In 2026, BioPorto will continue to build upon its human rights   framework, promoting our Whistleblower Scheme to ensure   even greater accessibility and confidentiality for employees.   The Company aim to foster an environment where human   rights are at the forefront of all our operations. Through   collaboration with theWork Environment Group and Corporate  Affairs, the Company will ensure that policies and practices   not only comply with legal requirements but also reflect our   dedication to ethical leadership and corporate responsibility.   Labor Rights   3. Businesses should uphold the freedom of association  and the effective recognition of the right to collective   bargaining;   4. the elimination of all forms of forced and compulsory  labor;   5. the effective abolition of child labor; and  6. the elimination of discrimination in respect of employ-  ment and occupation.   BioPorto upholds freedom of association, prohibits forced   labor and child labor, and enforces anti-discrimination policies.   Our Code of Conduct extends these standards to suppliers.   2025 Initiatives:   • Launched quarterly engagement surveys.   • Completed statutory workplace assessment (APV) with   follow-up actions planned for 2026.   • Recorded one minor work-related injury (slip accident),   reported and resolved through statutory channels.   • Zero union-related cases.   We continue to promote diversity and gender balance across   all levels.   Environment   BioPorto's operations have a limited environmental footprint;   however, we remain committed to minimizing impact and   promoting sustainable practices in line with the UN Global   Compact principles:   7. Support a precautionary approach to environmental  challenges.   8. Undertake initiatives to promote greater environmental  responsibility.   9. Encourage the development and diffusion of environ-  mentally friendly technologies   2025 Highlights:   • Continued preparations for CSRD compliance, while   awaiting the outcome of the Omnibus Directive to finalize   reporting requirements.   • Continued initiatives to reduce energy and water   consumption and foster climate-friendly practices across   all operations.   BioPorto acknowledges its relatively small environmental   footprint but remains committed to continuous improvement.   Any environmental incident would be reported immediately to   executive management, with corrective actions implemented   to prevent recurrence. No environmental incidents were   reported in 2025.   Anti-Corruption   10. Businesses should work against corruption in  all its forms, including extortion and bribery.   BioPorto enforces a zero-tolerance policy on corruption,   bribery, and money laundering. All employees receive anti-   corruption training during onboarding and regular training   after.   In 2025:   • Updated Code of Conduct and training programs to   strengthen awareness.   • Zero corruption incidents reported.   Risks   BioPorto's risk of impacting human rights, environment, or   anti-corruption remains low. Risks are assessed annually   based on operational significance and stakeholder impact.   No material risks have been identified.   In summary, BioPorto remains committed in our efforts   to uphold the highest standards of ethical conduct,   environmental conduct, and inclusivity as we keep our   ongoing commitment to transparency, accountability and   continuous improvement. Moving forward, we will continue   to embed these principles into our operations, championing a   workplace and corporate culture defined by respect, diversity,   and integrity. Together, we continue to build a stronger future   for BioPorto and all those we serve.   For further details on BioPorto’s broader business   risks, refer to the Risk Management section of this   Annual Report.  </mrv:DescriptionOfPoliciesOnSocialResponsibility>
   <mrv:StatementOfTheDiversityPolicies contextRef="ctx1" id="fact1302" xml:lang="en">Diversity   In pursuit of fostering an inclusive and equitable workplace   environment, BioPorto’s commitment to diversity remains steadfast   BioPorto’s Diversity Policy   Grounded in our core values of equality, respect, and integrity   and to support our continued work regarding diversity in 2026   BioPorto’s Board of Directors has adopted the following Policy:   “BioPorto is committed to fostering a diverse, inclusive and   equitable workplace across all entities in the Group. We believe   that diversity of gender, age, nationality, cultural background,   educational and professional experience, perspectives and   skills strengthens decisionmaking, promotes innovation and   supports longterm value creation in a highly regulated and   knowledgedriven biotech environment.   BioPorto is committed to ensuring equal opportunities for all   employees and applicants and does not tolerate discrimination   based on, inter alia, gender, gender identity or expression,   age, nationality, ethnicity, religion or belief, sexual orientation,   disability or other characteristics.   Employees shall be recognized and evaluated based on   competence, performance and potential, and we believe that   individuals should be recognized because of, not despite,   their diversity.   Diversity at Management and Board Level   BioPorto recognizes that diversity at leadership level is   essential to sound governance and effective oversight. The   Company therefore aims to promote balanced representation   and diversity at all management levels, including Executive   Management and the Board of Directors.   The Board of Directors is responsible for setting the overall   framework and ambition for diversity at leadership level and for   ensuring that diversity considerations form an integral part of:   • Board composition, succession planning and nomination   processes   • Executive appointment and development decisions   • Talent, leadership and succession pipelines within the   Group   BioPorto has established measurable diversity targets for the   Board of Directors, which are disclosed in the Annual Report,   page 38. Progress against these targets is reviewed regularly   and reported transparently.   Governance, Responsibilities and Review   The Board of Directors annually:   • Reviews the Company’s diversity policy and its relevance   • Assesses progress against the Company’s diversity   ambitions and disclosed targets   • Evaluates whether existing initiatives and processes   support sufficient diversity at management levels   Executive Management is responsible for implementing the   diversity policy through recruitment, talent management,   leadership development and workplace practices, supported   by Group HR.   This policy is reviewed at least annually and updated as required   to reflect changes in legislation, governance requirements or   business priorities."  Central to our commitment is the principle that all employees   should be valued and recognized for their unique perspectives,   talents, and contributions. We reject the notion of "fitting in" and   instead, champion a culture where every voice is heard, every   perspective is respected, and every individual is empowered   to thrive. As part of our ongoing efforts, BioPorto's Board of   Directors diligently reviews and evaluates our diversity initiatives   annually, reaffirming our dedication to fostering an inclusive   workplace where diversity is not just a goal but a lived reality.   Diversity in the BioPorto Group   In 2025, we noticed changes in our workforce composition   that affected both the gender-balance as well as the diversity   landscape. The proportion of male employees decreased from   46% to 41%. Additionally, the representation of non-Danish   employees decreased from 69% to 63%. We remain committed   to fostering a workplace where individuals from diverse   backgrounds can thrive, make meaningfully contributions,   and collectively drive our shared success.   Dec 31, 2025 BioPorto   Non-   Group   Female   Male   Danish   All Employees (46 persons)   59%   41%   63%   Executive Management   33%   67%   0%   (3 persons)   BioPorto A/S Board of Directors   25%   75%   50%   (4 persons)   Diversity in the Board of Directors of BioPorto A/S   Diversity in the composition of the Board is sought, with a   reasonable age composition, several nationalities, and an   equal gender ratio. The Board currently has four members,   of which three are male and one is female.   BioPorto currently meets the Danish Business Authority's re-   quirement for an equal gender ratio. In 2025, the composition   Board of Directors   2023   2024   2025   2026   2027   Number of Board   5 6 4 Members   Underrepresented   20%   17%   25%   gender in %   Target date   2027   2027   2027   Target number in %   40%   40%   40%   of the Company’s Board of Directors changed as three Board   Members stepped down and two new Board Members were   elected at the Annual General Assembly. Following a thorough   candidate selection process with a strong emphasis on gender   diversity, the highly qualified candidates Jens Due Olsen and   Donna Haire were presented to the AGM for election.   However, the company has decided to maintain its goal   that by 2027, at least 40% of the Board of Directors will be   comprised of the underrepresented gender, achieving equal   representation according to applicable law. This commitment   underscores our belief in promoting gender equality without   compromising the selection of the most qualified individuals   for these critical roles. This target is not intended to detract   from other competency requirements in the nomination of   members to the Management team of the Company.   Furthermore, the representation of non-Danish members on   the Board is 50%, highlighting the Company’s dedication to   integrating global perspectives and insights. This composition   ensures a broader range of viewpoints at the highest levels   of governance, strengthening strategic decision-making and   alignment with international best practices.   As of 31 December 2025, the following information applies to   the Board of Directors.   The Nomination &amp; Remuneration Committee has a policy   for evaluating candidates of both genders for vacant Board   positions. For future vacant Board positions, the Nomination &amp;   Remuneration committee will continue to evaluate candidates   of both genders.   Executive Management and Other Layers of Management   at BioPorto A/S   The Company has not set a target for the unrepresented   gender in the Executive Management and other layers of   the Management team, as the Company’s size is below the   minimum thresholds of 50 employees or more cf. guidelines   from the Danish Business Authority, section 4.1.2. The   Company has adopted a general Diversity Policy cf. above,   but the Company is below the threshold of 50 employees   or more cf. guidelines from the Danish Business Authority,   section 4.2 and accordingly not obligated to adopt a Policy.   As of 31 December 2025, and as of the date of this Annual   Report the following information applies to the Executive   Management.   Executive   Management   2023   2024   2025   2026   2027   Number of Members   1 3 3 Underrepresented   0% /   33%   33%   gender in %   100%   Target date   N/A   N/A   N/A   Target number in %   N/A   N/A   N/A  </mrv:StatementOfTheDiversityPolicies>
   <sob:StatementByExecutiveAndSupervisoryBoards contextRef="ctx1" id="fact1900" xml:lang="en">The Board of Directors and Executive Management   have today considered and approved the Annual   Report of BioPorto Group and BioProto A/S for the   period January 1 to December 31, 2025.   Statement by the Board of   Directors and Management   The consolidated financial statements have been prepared   in accordance IFRS Accounting Standards as adopted by the   EU and additional requirements for listed entities in Denmark.   The Parent Company Financial Statements are prepared in   accordance with the Danish Financial Statements Act.   In our opinion, the Consolidated Financial Statements and the   Parent Company Financial Statements give a true and fair view   of the financial position at December 31, 2025, of the Group   and the Parent Company and of the results of the Group and   Parent Company operations and consolidated cash flows for   the financial year January 1 to December 31, 2025.   In our opinion, Management’s commentary is prepared in   accordance with relevant laws and regulations, and includes a   fair review of the development in the operations and financial   circumstances of the Group and the Parent Company, of the   results for the year, and of the financial position of the Group   and the Parent Company in general, as well as a description of   the principal risks and uncertainties pertaining to the Group   and the Parent Company.   In our opinion, the Annual Report of the Group and the Parent   Company for the financial year January 1 to December 31,   2025, identified as BIOPORTO-2025-12-31-1-en.zip, has been   prepared, in all material respects, in compliance with the ESEF   Regulation.   We recommend the adoption of the Annual Report at the   Annual General Meeting.  </sob:StatementByExecutiveAndSupervisoryBoards>
   <cmn:NameAndSurnameOfMemberOfExecutiveBoard contextRef="ctx29" id="fact2377" xml:lang="en">Carsten Buhl</cmn:NameAndSurnameOfMemberOfExecutiveBoard>
   <cmn:TitleOfMemberOfExecutiveBoard contextRef="ctx29" id="fact2378" xml:lang="en">Chief Executive Officer</cmn:TitleOfMemberOfExecutiveBoard>
   <cmn:NameAndSurnameOfMemberOfExecutiveBoard contextRef="ctx30" id="fact2379" xml:lang="en">Niels Høy Nielsen</cmn:NameAndSurnameOfMemberOfExecutiveBoard>
   <cmn:TitleOfMemberOfExecutiveBoard contextRef="ctx30" id="fact2380" xml:lang="en">Chief Financial Officer</cmn:TitleOfMemberOfExecutiveBoard>
   <cmn:NameAndSurnameOfMemberOfExecutiveBoard contextRef="ctx31" id="fact2381" xml:lang="en">Gry Husby Larsen</cmn:NameAndSurnameOfMemberOfExecutiveBoard>
   <cmn:TitleOfMemberOfExecutiveBoard contextRef="ctx31" id="fact2382" xml:lang="en">Chief Legal Officer</cmn:TitleOfMemberOfExecutiveBoard>
   <cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx32" id="fact2383" xml:lang="en">Jens Due Olsen</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
   <cmn:TitleOfMemberOfSupervisoryBoard contextRef="ctx32" id="fact2384" xml:lang="en">Chair</cmn:TitleOfMemberOfSupervisoryBoard>
   <cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx33" id="fact2385" xml:lang="en">Henrik Juuel</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
   <cmn:TitleOfMemberOfSupervisoryBoard contextRef="ctx33" id="fact2386" xml:lang="en">Vice Chair</cmn:TitleOfMemberOfSupervisoryBoard>
   <cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx34" id="fact2387" xml:lang="en">Mats Thorén</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
   <cmn:TitleOfMemberOfSupervisoryBoard contextRef="ctx34" id="fact2388" xml:lang="en">Member</cmn:TitleOfMemberOfSupervisoryBoard>
   <cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx35" id="fact2389" xml:lang="en">Donna Haire</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
   <cmn:TitleOfMemberOfSupervisoryBoard contextRef="ctx35" id="fact2390" xml:lang="en">Member</cmn:TitleOfMemberOfSupervisoryBoard>
   <arr:IndependentAuditorsReportsAudit contextRef="ctx1" id="fact1944" xml:lang="en">Independent Auditor's Report Report on the consolidated financial statements and the parent financial statements</arr:IndependentAuditorsReportsAudit>
   <arr:AddresseeOfAuditorsReportOnAuditedFinancialStatements contextRef="ctx1" id="fact1947" xml:lang="en">To the shareholders of BioPorto A/S</arr:AddresseeOfAuditorsReportOnAuditedFinancialStatements>
   <arr:OpinionOnAuditedFinancialStatements contextRef="ctx1" id="fact1948" xml:lang="en">Opinion   We have audited the consolidated financial statements and  the parent financial statements of BioPorto A/S for  the financial year 01.01.2025 - 31.12.2025, which comprise  the income statement, balance sheet, statement of changes   in equity and notes, including material accounting policy   information, for the Group as well as the Parent, and the   statement of comprehensive income and the cash flow  statement of the Group. The consolidated financial statements  are prepared in accordance with IFRS Accounting Standards   as adopted by the EU and additional disclosure requirements   for listed entities in Denmark, and the parent financial  statements are prepared in accordance with the Danish   Financial Statements Act.   In our opinion, the consolidated financial statements give  a true and fair view of the Group’s financial position at  31.12.2025, and of the results of its operations and cash flows  for the financial year 01.01.2025 - 31.12.2025 in accordance  with IFRS Accounting Standards as adopted by the EU and   additional disclosure requirements for listed entities in   Denmark.   Furthermore, in our opinion, the parent financial statements  give a true and fair view of the Parent’s financial position at  31.12.2025, and of the results of its operations for the financial  year 01.01.2025 - 31.12.2025 in accordance with the Danish   Financial Statements Act.   Our opinion is consistent with our audit book comments   issued to the Audit Committee and the Board of Directors.  </arr:OpinionOnAuditedFinancialStatements>
   <arr:DescriptionOfQualificationsOfAuditedFinancialStatements contextRef="ctx1" id="fact2002" xml:lang="en">Basis for opinion   We conducted our audit in accordance with International   Standards on Auditing (ISAs) and the additional requirements   applicable in Denmark. Our responsibilities under those   standards and requirements are further described in the   "Auditor’s responsibilities for the audit of the consolidated   financial statements and the parent financial statements"  section of this auditor’s report. We are independent of the   Group in accordance with the International Ethics Standards   Board for Accountants’ International Code of Ethics for   Professional Accountants (IESBA Code), as applicable to   audits of financial statements of public interest entities, and  the additional ethical requirements applicable in Denmark   to audits of financial statements of public interest entities.  We have also fulfilled our other ethical responsibilities in  accordance with these requirements and the IESBA Code. We   believe that the audit evidence we have obtained is sufficient   and appropriate to provide a basis for our opinion.   To the best of our knowledge and belief, we have not provided   any prohibited non-audit services as referred to in Article 5(1)   of Regulation (EU) No 537/2014.   We were appointed auditors of BioPorto A/S for the first  time on 23.11.2022 for the financial year 2022. We have been  reappointed annually by decision of the general meeting for   a total contiguous engagement period of 4 years up to and   including the financial year 2025.  </arr:DescriptionOfQualificationsOfAuditedFinancialStatements>
   <arr:KeyAuditMattersAudit contextRef="ctx1" id="fact2043" xml:lang="en">Key audit matters   We have determined that there are no key audit matters to   communicate in our report.  </arr:KeyAuditMattersAudit>
   <arr:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements contextRef="ctx1" id="fact2046" xml:lang="en">Statement on the management commentary   Management is responsible for the management commentary.   Our opinion on the consolidated financial statements and the  parent financial statements does not cover the management  commentary, and we do not express any form of assurance   conclusion thereon.   In connection with our audit of the consolidated financial  statements and the parent financial statements, our  responsibility is to read the management commentary and,   in doing so, consider whether the management commentary   is materially inconsistent with the consolidated financial  statements and the parent financial statements or our  knowledge obtained in the audit or otherwise appears to be   materially misstated.   Moreover, it is our responsibility to consider whether the   management commentary provides the information required   by relevant law and regulations.   Based on the work we have performed, we conclude that   the management commentary is in accordance with the   consolidated financial statements and the parent financial  statements and has been prepared in accordance with the   requirements of the relevant law and regulations. We did   not identify any material misstatement of the management   commentary.  </arr:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements>
   <arr:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed contextRef="ctx1" id="fact2126" xml:lang="en">Auditor's responsibilities for the audit of the consolidated   financial statements and the parent financial statements  Our objectives are to obtain reasonable assurance about   whether the consolidated financial statements and the  parent financial statements as a whole are free from material  misstatement, whether due to fraud or error, and to issue   an auditor’s report that includes our opinion. Reasonable   assurance is a high level of assurance, but is not a guarantee   that an audit conducted in accordance with ISAs and the   additional requirements applicable in Denmark will always   detect a material misstatement when it exists. Misstatements   can arise from fraud or error and are considered material if,   individually or in the aggregate, they could reasonably be   expected to influence the economic decisions of users taken  on the basis of these consolidated financial statements and  these parent financial statements.  As part of an audit conducted in accordance with ISAs and the   additional requirements applicable in Denmark, we exercise   professional judgement and maintain professional scepticism   throughout the audit. We also:   • Identify and assess the risks of material misstatement   of the consolidated financial statements and the parent  financial statements, whether due to fraud or error,  design and perform audit procedures responsive to those   risks, and obtain audit evidence that is sufficient and   appropriate to provide a basis for our opinion. The risk   of not detecting a material misstatement resulting from   fraud is higher than for one resulting from error, as fraud   may involve collusion, forgery, intentional omissions,   misrepresentations, or the override of internal control.   • Obtain an understanding of internal control relevant   to the audit in order to design audit procedures that   are appropriate in the circumstances, but not for the   purpose of expressing an opinion on the effectiveness   of the Group’s and the Parent’s internal control.   • Evaluate the appropriateness of accounting policies used   and the reasonableness of accounting estimates and   related disclosures made by Management.   • Conclude on the appropriateness of Management’s use   of the going concern basis of accounting in preparing   the consolidated financial statements and the parent  financial statements, and, based on the audit evidence  obtained, whether a material uncertainty exists related to   events or conditions that may cast significant doubt on  the Group's and the Parent’s ability to continue as a going   concern. If we conclude that a material uncertainty exists,   we are required to draw attention in our auditor’s report   to the related disclosures in the consolidated financial  statements and the parent financial statements or, if such  disclosures are inadequate, to modify our opinion. Our   conclusions are based on the audit evidence obtained   up to the date of our auditor’s report. However, future   events or conditions may cause the Group and the Entity   to cease to continue as a going concern.   • Evaluate the overall presentation, structure and content   of the consolidated financial statements and the parent  financial statements, including the disclosures in the notes,  and whether the consolidated financial statements and  the parent financial statements represent the underlying  transactions and events in a manner that gives a true   and fair view.   • Plan and perform the group audit to obtain sufficient   appropriate audit evidence regarding the financial  information of the entities or business units within the   group as a basis for forming an opinion on the consolidated   financial statements and the parent financial statements.  We are responsible for the direction, supervision and   review of the audit work performed for purposes of the   group audit. We remain solely responsible for our audit   opinion.   We communicate with those charged with governance   regarding, among other matters, the planned scope and   timing of the audit and significant audit findings, including  any significant deficiencies in internal control that we identify  during our audit.   We also provide those charged with governance with   a statement that we have complied with relevant ethical   requirements regarding independence, and to communicate   with them all relationships and other matters that may   reasonably be thought to bear on our independence, and,   where applicable, safeguards put in place and measures taken   to eliminate threats.   From the matters communicated with those charged with   governance, we determine those matters that were of   most significance in the audit of the consolidated financial  statements and the parent financial statements of the current  period and are therefore the key audit matters. We describe   these matters in our auditor’s report unless law or regulation   precludes public disclosure about the matter.  </arr:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed>
   <arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements contextRef="ctx1" id="fact2086" xml:lang="en">Management's responsibilities for the consolidated financial  statements and the parent financial statements  Management is responsible for the preparation of consolidated   financial statements that give a true and fair view in accordance  with IFRS Accounting Standards as adopted by the EU   and additional disclosure requirements for listed entities   in Denmark as well as the preparation of parent financial  statements that give a true and fair view in accordance with   the Danish Financial Statements Act, and for such internal   control as Management determines is necessary to enable the   preparation of consolidated financial statements and parent  financial statements that are free from material misstatement,  whether due to fraud or error.   In preparing the consolidated financial statements and the  parent financial statements, Management is responsible for  assessing the Group’s and the Parent’s ability to continue as   a going concern, for disclosing, as applicable, matters related   to going concern, and for using the going concern basis of   accounting in preparing the consolidated financial statements  and the parent financial statements unless Management  either intends to liquidate the Group or the Entity or to cease   operations, or has no realistic alternative but to do so.  </arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements>
   <arr:AuditorsReportOnXbrlTagging contextRef="ctx1" id="fact2272" xml:lang="en">Report on compliance with the ESEF Regulation   As part of our audit of the consolidated financial statements  and the parent financial statements of BioPorto A/S we  performed procedures to express an opinion on whether the   annual report for the financial year 01.01.2025 - 31.12.2025,  with the file name BIOPORTO-2025-12-31-1-en.zip is prepared,  in all material respects, in compliance with the Commission   Delegated Regulation (EU) 2019/815 on the European   Single Electronic Format (ESEF Regulation), which includes   requirements related to the preparation of the annual report in   XHTML format and iXBRL tagging of the consolidated financial  statements including notes.   Management is responsible for preparing an annual report   that complies with the ESEF Regulation. This responsibility   includes:   • The preparing of the annual report in XHTML format;   • The selection and application of appropriate iXBRL   tags, including extensions to the ESEF taxonomy and   the anchoring thereof to elements in the taxonomy,   for financial information required to be tagged using  judgement where necessary;   • Ensuring consistency between iXBRL tagged data and the   consolidated financial statements presented in human  readable format; and   For such internal control as Management determines   necessary to enable the preparation of an annual report   that is compliant with the ESEF Regulation.   Our responsibility is to obtain reasonable assurance on   whether the annual report is prepared, in all material respects,   in compliance with the ESEF Regulation based on the evidence   we have obtained, and to issue a report that includes our   opinion. The nature, timing and extent of procedures selected   depend on the auditor’s judgement, including the assessment   of the risks of material departures from the requirements set   out in the ESEF Regulation, whether due to fraud or error. The   procedures include:   • Testing whether the annual report is prepared in XHTML   format;   • Obtaining an understanding of the company’s iXBRL   tagging process and of internal control over the tagging   process;   • Evaluating the completeness of the iXBRL tagging of the   consolidated financial statements including notes;  • Evaluating the appropriateness of the company’s use of   iXBRL elements selected from the ESEF taxonomy and   the creation of extension elements where no suitable   element in the ESEF taxonomy has been identified;  • Evaluating the use of anchoring of extension elements   to elements in the ESEF taxonomy; and   • Reconciling the iXBRL tagged data with the audited   consolidated financial statements.  In our opinion, the annual report of BioPorto A/S for the   financial year 01.01.2025 - 31.12.2025, with the file name  BIOPORTO-2025-12-31-1-en.zip, is prepared, in all material   respects, in compliance with the ESEF Regulation.  </arr:AuditorsReportOnXbrlTagging>
   <arr:SignatureOfAuditorsPlace contextRef="ctx1" id="fact2359" xml:lang="en">Copenhagen</arr:SignatureOfAuditorsPlace>
   <arr:SignatureOfAuditorsDate contextRef="ctx1" id="fact2360">2026-03-26</arr:SignatureOfAuditorsDate>
   <cmn:NameOfAuditFirm contextRef="ctx38" id="fact2401" xml:lang="en">Deloitte Statsautoriseret Revisionspartnerselskab</cmn:NameOfAuditFirm>
   <cmn:NameOfAuditFirm contextRef="ctx37" id="fact2391" xml:lang="en">Deloitte Statsautoriseret Revisionspartnerselskab</cmn:NameOfAuditFirm>
   <cmn:IdentificationNumberCvrOfAuditFirm contextRef="ctx38" id="fact2400">33963556</cmn:IdentificationNumberCvrOfAuditFirm>
   <cmn:IdentificationNumberCvrOfAuditFirm contextRef="ctx37" id="fact2393">33963556</cmn:IdentificationNumberCvrOfAuditFirm>
   <cmn:NameAndSurnameOfAuditor contextRef="ctx37" id="fact2394" xml:lang="en">KÃ¥re Kansonen Valtersdorf</cmn:NameAndSurnameOfAuditor>
   <cmn:DescriptionOfAuditor contextRef="ctx37" id="fact2395" xml:lang="en">State Authorised Public Accountant</cmn:DescriptionOfAuditor>
   <cmn:IdentificationNumberOfAuditor contextRef="ctx37" id="fact2396" xml:lang="en">mne34490</cmn:IdentificationNumberOfAuditor>
   <cmn:NameAndSurnameOfAuditor contextRef="ctx38" id="fact2397" xml:lang="en">Lars Hansen</cmn:NameAndSurnameOfAuditor>
   <cmn:DescriptionOfAuditor contextRef="ctx38" id="fact2398" xml:lang="en">State Authorised Public Accountant</cmn:DescriptionOfAuditor>
   <cmn:IdentificationNumberOfAuditor contextRef="ctx38" id="fact2399" xml:lang="en">mne24828</cmn:IdentificationNumberOfAuditor>
</xbrli:xbrl>